山东大学耳鼻喉眼学报 ›› 2022, Vol. 36 ›› Issue (2): 32-39.doi: 10.6040/j.issn.1673-3770.0.2021.119

• • 上一篇    下一篇

CHD1L通过EMT促进喉鳞状细胞癌细胞的增殖、侵袭和转移

刘勇1,袁存立1,曹慧1,郑成彩1,晁方2, 许风雷3   

  1. 1.日照市中心医院 耳鼻喉科, 山东 日照 276800;
    2.日照市人民医院 第一手术室, 山东 日照 276826;
    3.山东省立医院 耳鼻喉科, 山东 济南 250022
  • 发布日期:2022-04-15
  • 通讯作者: 许风雷. E-mail:xufenglei@sdu.edu.cn
  • 基金资助:
    山东省重点研发项目基金(2018GSF118091)

CHD1L promotes proliferation, invasion and metastasis of laryngeal squamous cell carcinoma cells by EMT

LIU Yong1, YUAN Cunli1, CAO Hui1, ZHENG Chengcai1, CHAO Fang2, XU Fenglei3   

  1. 1.Department of Otolaryngology, Rizhao Central Hospital, Rizhao 276800, Shandong, China;
    2.First Operating Room, Rizhao People's Hospital, Rizhao 276826, Shandong, China;
    3. Department of Otolaryngology, Shandong Provincial Hospital, Jinan 250022, Shandong, China
  • Published:2022-04-15

PDF (PC)

365

摘要： 目的 探讨染色质解旋酶DNA结合蛋白(CHD1L)在喉鳞状细胞癌(LSCC)增殖、侵袭和转移中的作用机制,为喉鳞状细胞癌的治疗提供分子靶点。 方法 免疫组织化学方法检测60例喉鳞状细胞癌组织和其配对癌旁正常黏膜组织中CHD1L、上皮性钙黏着蛋白(E-cadherin)和波形蛋白(Vimentin)的表达;Western blotting法检测人支气管上皮细胞(HBE)和人喉表皮样癌细胞(HEp-2)中CHD1L表达。敲除HEp-2细胞中的CHD1L,并用Western blotting法检测HEp-2细胞内CHD1L、E-cadherin和Vimentin的表达;CCK-8实验检测各组细胞增殖情况,Transwell侵袭实验检测各组细胞的侵袭情况。 结果 免疫组化结果显示CHD1L在喉鳞状细胞癌组织中的阳性表达率明显高于癌旁正常黏膜组织中的阳性表达率,且其阳性表达与喉鳞状细胞癌的分化程度、淋巴结转移、临床分期及Vimentin的表达呈正相关,而与E-cadherin的表达呈负相关(P<0.05)。Western blotting结果显示CHD1L在HEp-2细胞中的表达明显高于HBE细胞。用干扰质粒体外敲减HEp-2细胞中的CHD1L。体外敲减CHD1L的表达水平之后,HEp-2细胞的增殖能力及侵袭能力明显降低,E-cadherin的表达明显升高,Vimentin的表达明显降低。 结论 喉鳞状细胞癌组织中CHD1L呈高表达,与喉鳞状细胞癌细胞分化程度、临床分期及淋巴结转移密切相关,提示CHD1L在喉鳞状细胞癌中起着癌基因的作用;CHD1L可以通过促进喉鳞状细胞癌细胞的EMT进而促进喉鳞状细胞癌细胞的增殖、侵袭和转移。

关键词: 喉鳞状细胞癌, 染色质解旋酶DNA结合蛋白, 上皮-间充质转化, 增殖, 侵袭, 转移

Abstract: Objective To investigate the mechanism of chromodomain helicase DNA binding protein 1-like gene(CHD1L )in the proliferation, invasion and metastasis of laryngeal squamous cell carcinoma cells and to provide molecular targets for the treatment of laryngeal squamous cell carcinoma(LSCC). Methods Immunohistochemistry was conducted to measure the expression of CHD1L, E-cadherin and Vimentin in 60 pairs of LSCC and its adjacent normal mucosa. The expression of CHD1L in human bronchial epithelial cell(HBE)and human laryngeal epithelioid carcinoma cell(HEp-2)was detected by Western blotting. CHD1L in HEp-2 cells was knocked out, and Western blotting was used to detect the expression of CHD1L, E-cadherin and Vimentin in HEp-2 cells. The proliferation of cells in each group was detected by CCK-8 kit, and the invasion of cells in each group was detected by Transwell invasion test. Results Immunohistochemical results showed that the positive expression rate of CHD1L in laryngeal squamous cell carcinoma tissue was significantly higher than that of normal paracaner mucosa tissues. In addition, the expression of CHD1L was positively correlated with the degree of differentiation of laryngeal squamous cell carcinoma, the lymph node metastasis, the clinical stage and the expression of Vimentin, but negatively correlated with the expression of E-cadherin(P<0.05). The results of Western blotting showed that the expression of CHD1L in HEp-2 cell was significantly higher than that in HBE cell. CHD1L in HEp-2 cells was knocked down by interfering plasmid in vitro. The proliferation and invasion ability of the HEp-2 cells with CHD1L knockdown in vitro were significantly decreased, while the expression of E-cadherin was significantly increased and the expression of Vimentin was also significantly decreased. Conclusion The high expression of CHD1L in LSCC was closely related to pathological grades, clinical stage and risk of lymph node metastasis of LSCC, suggesting that CHD1L may play an oncogene role in LSCC; CHD1L could promote the proliferation, invasion and metastasis of LSCC cells by promoting the EMT of LSCC cells.

Key words: Laryngeal squamous cell carcinoma, Chromodomain helicase/ATPase DNA binding protein 1-like gene, Epithelial-mesenchymal transition, Proliferation, Invasion, Metastasis

中图分类号: 

  • R739.65
[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(1): 7-30. doi:10.3322/caac.21442.
[2] Tang X, Sun Y, Wan G, et al. Knockdown of YAP inhibits growth in Hep-2 laryngeal cancer cells via epithelial-mesenchymal transition and the Wnt/β-catenin pathway[J]. BMC Cancer, 2019, 19(1): 654.doi:10.1186/s12885-019-5832-9.
[3] 蒋宏,王斌全,高泽慧,等.喉癌患者情绪和认知功能改变的研究进展[J].临床耳鼻咽喉头颈外科杂志,2018,32(11):880-882. doi:10.13201/j.issn.1001-1781.2018.11.021. JIANG Hong, WANG Binquan, GAO Zehui, et al. Research progress on the changes of emotional and cognitive functions in patients with laryngeal cancer[J]. Journal of Clinical Otorhinolaryngology Head and Neck Surgery, 2018, 32(11): 880-882. doi:10.13201/j.issn.1001-1781.2018.11.021.
[4] Liu ZH, Zhang Q, Ding YJ, et al. Overexpression of CHD1L is associated with poor survival and aggressive tumor biology in esophageal carcinoma[J]. Oncotarget, 2017, 8(43): 74178-74187.doi:10.18632/oncotarget.18830.
[5] Li SM, Chai Y, Ding YB, et al. CHD1L is associated with poor survival and promotes the proliferation and metastasis of intrahepatic cholangiocarcinoma[J]. Oncol Rep, 2019, 42(2): 657-669.doi:10.3892/or.2019.7174.
[6] Mu QJ, Li HL, Yao Y, et al. Chromodomain helicase/ATPase DNA-binding protein 1-like gene(CHD1L)expression and implications for invasion and metastasis of breast cancer[J]. PLoS One, 2015, 10(11): e0143030. doi:10.1371/journal.pone.0143030.
[7] Nieto MA, Huang RYJ, Jackson RA, et al. Emt: 2016[J]. Cell, 2016, 166(1): 21-45. doi:10.1016/j.cell.2016.06.028.
[8] Su Z, Zhao J, Xian G, et al. CHD1L is a novel independent prognostic factor for gastric cancer[J]. Clin Transl Oncol, 2014, 16(8): 702-707. doi:10.1007/s12094-013-1136-8.
[9] Famokunwa B, Walsted ES, Hull JH. Assessing laryngeal function and hypersensitivity[J]. Pulm Pharmacol Ther, 2019, 56: 108-115. doi:10.1016/j.pupt.2019.04.003.
[10] Al-Rohil RN, Tarasen AJ, Carlson JA, et al. Evaluation of 122 advanced-stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies[J]. Cancer, 2016, 122(2): 249-257. doi:10.1002/cncr.29738.
[11] Peyvandi H, Peyvandi AA, Safaei A, et al. Introducing potential key proteins and pathways in human laryngeal cancer: a system biology approach[J]. Iran J Pharm Res, 2018, 17(1): 415-425.
[12] Liu W, Xu J, Zhang C. Prognostic role of chromodomain helicase DNA binding protein 1-like protein in human solid cancers: a meta-analysis[J]. Medicine(Baltimore), 2018, 97(29): e11522.doi:10.1097/md.0000000000011522.
[13] Li Y, He LR, Gao Y, et al. CHD1L contributes to cisplatin resistance by upregulating the ABCB1-NF-κB axis in human non-small-cell lung cancer[J]. Cell Death Dis, 2019, 10(2): 99. doi:10.1038/s41419-019-1371-1.
[14] Su FR, Ding JH, Bo L, et al. Chromodomain helicase/ATPase DNA binding protein 1-like protein expression predicts poor prognosis in nasopharyngeal carcinoma[J]. Exp Ther Med, 2014, 8(6): 1745-1750. doi:10.3892/etm.2014.2017.
[15] Tian F, Xu F, Zhang ZY, et al. Expression of CHD1L in bladder cancer and its influence on prognosis and survival[J]. Tumour Biol, 2013, 34(6): 3687-3690. doi:10.1007/s13277-013-0951-4.
[16] Wang W, Wu J, Fei X, et al. CHD1L promotes cell cycle progression and cell motility by up-regulating MDM2 in breast cancer[J]. Am J Transl Res, 2019,11(3):1581-1592.
[17] He LR, Ma NF, Chen JW, et al. Overexpression of CHD1L is positively associated with metastasis of lung adenocarcinoma and predicts patients poor survival[J]. Oncotarget, 2015, 6(31): 31181-31190.doi:10.18632/oncotarget.5070.
[18] Skrypek N, Goossens S, De Smedt E, et al. Epithelial-to-mesenchymal transition: epigenetic reprogramming driving cellular plasticity[J]. Trends Genet, 2017, 33(12): 943-959.doi:10.1016/j.tig.2017.08.004.
[19] Nakagawa H, Hikiba Y, Hirata Y, et al. Loss of liver E-cadherin induces sclerosing cholangitis and promotes carcinogenesis[J]. PNAS, 2014, 111(3): 1090-1095. doi:10.1073/pnas.1322731111.
[20] Po JW, Roohullah A, Lynch D, et al. Improved ovarian cancer EMT-CTC isolation by immunomagnetic targeting of epithelial EpCAM and mesenchymal N-cadherin[J]. J Circ Biomark, 2018, 7: 184945441878261. doi:10.1177/1849454418782617.
[21] Li T, Xie J, Shen C, et al. Upregulation of long noncoding RNA ZEB1-AS1 promotes tumor metastasis and predicts poor prognosis in hepatocellular carcinoma[J]. Oncogene, 2016, 35(12): 1575-1584.doi:10.1038/onc.2015.223.
[22] Matysiak M, Kapka-Skrzypczak L, Jodowska-Jędrych B, et al. EMT promoting transcription factors as prognostic markers in human breast cancer[J]. Arch Gynecol Obstet, 2017, 295(4): 817-825.doi:10.1007/s00404-017-4304-1.
[23] Mizukoshi K, Okazawa Y, Haeno H, et al. Metastatic seeding of human colon cancer cell clusters expressing the hybrid epithelial/mesenchymal state[J]. Int J Cancer, 2020, 146(9): 2547-2562.doi:10.1002/ijc.32672.
[24] Karlsson MC, Gonzalez SF, Welin J, et al. Epithelial-mesenchymal transition in cancer metastasis through the lymphatic system[J]. Mol Oncol, 2017, 11(7): 781-791. doi:10.1002/1878-0261.12092.
[25] Karamagkiolas S, Giotakis I, Kyrodimos E, et al. Expression of vimentin(VIM)and metastasis-associated 1(MTA1)protein in laryngeal squamous cell carcinoma are associated with prognostic outcome of patients[J]. Am J Otolaryngol, 2019, 40(4): 487-493. doi:10.1016/j.amjoto.2019.04.002.
[26] Mezi S, Chiappetta C, Carletti R, et al. Clinical significance of epithelial-to-mesenchymal transition in laryngeal carcinoma: Its role in the different subsites[J]. Head Neck, 2017, 39(9): 1806-1818.doi:10.1002/hed.24838.
[27] Haga RB, Ridley AJ. Rho GTPases: Regulation and roles in cancer cell biology[J]. Small GTPases, 2016, 7(4): 207-221. doi:10.1080/21541248.2016.1232583.
[28] Liu M, Chen LL, Ma NF, et al. CHD1L promotes lineage reversion of hepatocellular carcinoma through opening chromatin for key developmental transcription factors[J]. Hepatology, 2016, 63(5): 1544-1559. doi:10.1002/hep.28437.
[29] Li FF, Zhang Z, Wang P, et al. ALC1 knockdown enhances cisplatin cytotoxicity of esophageal squamous cell carcinoma cells by inhibition of glycolysis through PI3K/Akt pathway[J]. Life Sci, 2019,232: 116679. doi:10.1016/j.lfs.2019.116679.
[1] 胡祎,孔旭辉. 补体在喉鳞状细胞癌发生发展中作用机制的研究进展[J]. 山东大学耳鼻喉眼学报, 2025, 39(5): 148-155.
[2] 沈文浩,陈曦. 双能CT在喉鳞状细胞癌诊疗中的运用[J]. 山东大学耳鼻喉眼学报, 2025, 39(5): 156-160.
[3] 李芃泽,于霜,王加锋. 男性喉局部淀粉样变发生与谷丙转氨酶异常相关性[J]. 山东大学耳鼻喉眼学报, 2025, 39(3): 135-140.
[4] 杨鸣,刘雪霞,张华. m6A识别蛋白IGF2BPs家族在头颈肿瘤中的研究进展[J]. 山东大学耳鼻喉眼学报, 2025, 39(3): 153-161.
[5] 辛梦,纪芳,代春华,张靖,刘澍. 医用透明质酸钠与平衡盐溶液在微创玻璃体手术中对眼表保护的影响[J]. 山东大学耳鼻喉眼学报, 2024, 38(5): 58-65.
[6] 吴翠萍,朱一丹,李春燕,殷善开. 胆红素对神经干细胞活性和增殖的影响研究[J]. 山东大学耳鼻喉眼学报, 2024, 38(4): 1-6.
[7] 张琳,辛运超,尚小领,解琪,刘亚超. cN0期甲状腺微小乳头状癌颈部中央区及侧颈区淋巴结转移率、危险因素及清扫策略的临床研究[J]. 山东大学耳鼻喉眼学报, 2024, 38(4): 62-69.
[8] 袁玥,庞文会,陈敏,付圣尧,于龙刚,孙钰博,李玲玲. 毛霉菌性鼻窦炎25例临床特征分析[J]. 山东大学耳鼻喉眼学报, 2024, 38(4): 102-107.
[9] 吴彬,周敬淳. 单细胞测序分析喉鳞状细胞癌细胞RPN2表达模式[J]. 山东大学耳鼻喉眼学报, 2024, 38(3): 1-11.
[10] 王靖淞,余灿,张西,邓启成,谢卓良,赵锐,温蓓,刘海. KRT4在喉癌及癌旁正常黏膜组织中的表达及临床意义[J]. 山东大学耳鼻喉眼学报, 2024, 38(3): 12-17.
[11] 王凯健,陈雪生,王威. 血小板-淋巴细胞比值与喉鳞状细胞癌预后相关性的Meta分析[J]. 山东大学耳鼻喉眼学报, 2024, 38(3): 67-73.
[12] 谢玉林,雷大鹏. 人工智能在头颈部鳞状细胞癌淋巴结转移的病理研究进展[J]. 山东大学耳鼻喉眼学报, 2024, 38(3): 124-129.
[13] 王腾,余林,李穗. 血清γ-谷氨酰基转移酶与阻塞性睡眠呼吸暂停综合征伴发高血压的相关性研究[J]. 山东大学耳鼻喉眼学报, 2023, 37(6): 80-84.
[14] 张永红,张辉,王彩华,杨欣欣,吴允刚,赵玉凤,庞太忠,李晓瑜. 基于TCGA数据库构建喉鳞状细胞癌免疫相关基因预后模型及筛选靶向分子药物[J]. 山东大学耳鼻喉眼学报, 2023, 37(5): 54-62.
[15] 王玉冰,郑跃彬,杨羿容,鄢斌成,彭顺林. 颈部转移性Merkel细胞癌1例并文献复习[J]. 山东大学耳鼻喉眼学报, 2023, 37(2): 51-55.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
网站版权所有 © 2018 《山东大学耳鼻喉眼学报》编辑部　
地址：山东省济南市山大南路27号（250100）电话：+86-0531-88366912 E-mail: ebhxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发